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Abstract
Although it is now known that the human body is colo-
nized by a wide variety of microbial populations in dif-
ferent parts (such as the mouth, pharynx and respirato-
ry system, the skin, the gastro- and urogenital tracts), 
many effects of the complex interactions between the 
human host and microbial symbionts are still not com-
pletely understood. The dysbiosis of the gastrointesti-
nal tract microbiota is considered to be one of the most 
important contributing factors in the development of 
many gastrointestinal diseases such as inflammatory 
bowel disease, irritable bowel syndrome and colorec-
tal cancer, as well as systemic diseases like obesity, 
diabetes, atherosclerosis and non-alcoholic fatty liver 
disease. Fecal microbial transplantations appear to be 
promising therapies for dysbiosis-associated diseases; 
however, probiotic microorganisms have been grow-
ing in popularity due to increasing numbers of studies 
proving that certain strains present health promoting 
properties, among them the beneficial balance of the 
intestinal microbiota. Inflammatory bowel diseases and 
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obesity are the pathologies in which there are more 
studies showing this beneficial association using animal 
models and even in human clinical trials. In this review, 
the association of the human gut microbiota and hu-
man health will be discussed along with the benefits 
that probiotics can confer on this symbiotic activity and 
on the prevention or treatment of associated diseases.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: The human body is colonized by a wide vari-
ety of microorganisms that constantly interact with the 
host. The dysbiosis of the gut microbiota is considered 
to be one of the most important contributing factors in 
the development of gastrointestinal as well as systemic 
diseases. Many studies relate the health promoting 
properties of probiotic microorganisms with a beneficial 
balance of the host intestinal microbiota. In this review, 
the association of the human gut microbiota and hu-
man health will be discussed along with the benefits 
that probiotics can confer on this symbiotic activity and 
on the prevention or treatment of associated diseases.
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INTRODUCTION
In February 2014, if  one performed a MEDLINE search 
using the keywords “probiotics” crossed with “microbi-
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ota” or “microbiome”, the total hits would be over 1294 
articles. From these, almost 75% (962) were published 
in the last 5 years (between 2009 and the beginning of  
2014) showing that the association between probiotics 
and microbiota is not only recent but also is gaining the 
attention of  scientists from around the worlds. The ob-
jective of  this review is to give an overview of  the most 
recent studies that have shown that the use of  probiotics 
can modify the human microbiota and in turn can help in 
the prevention or treatment of  a growing number of  dis-
eases that can be caused by a dysbiosis in the microbiota 
composition.
DEFINITIONS
Before going any further, it is important to clearly de-
fine the 2 terms that are going to be described in this 
review, probiotics and microbiota. The most commonly 
accepted definition of  probiotics was published by the 
World Health Organization/Food and Agricultural Or-
ganization in 2001 that stated that probiotics are “live 
microorganisms which when administered in adequate 
amounts confer a health benefit to the host”[1]. However, 
according to the International Scientific Association for 
Probiotics and Prebiotics (ISAPP), a non-profit scientific 
organization dedicated to advancing the science of  pro-
biotics and prebiotics, the term probiotic is commonly 
misused both commercially, when the term is featured on 
products with no substantiation of  human health ben-
efits, and scientifically, where the term has been used to 
describe bacterial components, dead bacteria or bacteria 
with uncharacterized health effects in humans (http://
www.isapp.net/Portals/0/docs/ProbioticDefinitionClari-
fication.pdf). The ISAPP does not provide a new defini-
tion for probiotics, it simply points out the important ele-
ments that are contained in the FAO/WHO definition. 
This being said, they clarify that a probiotic must: (1) be 
alive when administered; (2) have undergone controlled 
evaluation to document health benefits in the target host; 
(3) be a taxonomically defined microbe or combination 
of  microbes (genus, species and strain level); and (4) be 
safe for its intended use.
Although the terms are sometimes used synony-
mously, “microbiome” and “microbiota” are terms that 
describe either the collective genomes of  the microor-
ganisms that reside in an environmental niche or the 
microorganisms themselves, respectively[2-4]. The term 
“microflora” is an equivalent term for “microbiota” that 
was used in the past and still appears in recent articles. 
The term “microbiota” is thus “the microscopic living 
organisms of  a region” or “the microorganisms of  a 
particular site, habitat, or geological period” according to 
the Dorland’s Medical Dictionary for Health Consumers 
(2007) and the Oxford Dictionary, respectively. 
A keyword that has gained a lot of  attention is “the 
human holobiont”. In this theory, humans did not evolve 
as a single species instead they evolved with a complex-
associated microbiota, building a kind of  “superorgan-
ism” or holobiont[5]. The human superorganism is a 
conglomerate of  mammalian and microbial cells, with the 
latter estimated to outnumber the former by ten to one 
and the microbial genetic repertoire (microbiome) to be 
approximately 100-times greater than that of  the human 
host[6]. The association between the host and its micro-
biota (also referred to as symbiote) provides a mutual 
beneficial relationship. It has recently been shown that 
the symbiote not only protects the host from pathogens 
but also decreases immune disorders by immunomodula-
tion; while the host provides shelter and nutrients to the 
symbiote, the symbiote in turn also improve various body 
functions such as digestion to provide essential nutrients 
to the host[7].
Although it is now known that the human body is 
colonized by a wide variety of  microbial populations in 
different parts of  the human body (such as the mouth, 
pharynx and respiratory system, the skin, the gastro- and 
urogenital tracts), many effects of  these complex interac-
tions are still not completely understood. In this review, 
the association of  the human gut microbiota and human 
health will be discussed along with the benefits that pro-
biotics can confer on this symbiotic activity and on the 
prevention or treatment of  associated diseases.
EFFECT OF THE HUMAN INTESTINAL 
MICROBIOTA ON HEALTH AND 
DISEASES
The human body has over 1014 microorganisms in the 
gastro-intestinal tract (GIT), literally 10 times more than 
the cells of  the entire human body itself. In the past, it 
was thought that this microbiota was useful for the host 
because they could contribute nutrients and energy via 
the fermentation of  non-digestible dietary components 
in the large intestine. Now, it is recognized that the mi-
crobiota is also extremely important to human health due 
to the emergence of  studies that have shown that a dys-
biosis of  the GIT microbiota can cause diseases or that 
in certain diseases there is an observable change in the 
composition of  this microbiota.
According to a recent review, a healthy microbiota is 
defined by high diversity and an ability to resist change 
under physiological stress; in contrast, microbiota associ-
ated with disease is defined by lower species diversity, 
fewer beneficial microbes and/or the presence of  patho-
bionts[8]. In this review, diet-induced dysbiosis was de-
scribed to be a contributing factor in the development of  
gastrointestinal diseases like inflammatory bowel disease, 
irritable bowel syndrome and colorectal cancer (CRC), 
as well as systemic diseases like obesity, diabetes, athero-
sclerosis and non-alcoholic fatty liver disease (NAFLD) 
(Figure 1).
The close proximity of  the GIT microbiota with the 
mucosa and gut lymphoid tissue helps explain why a bal-
anced microbiota is likely to preserve mucosal health, 
whereas an unbalanced composition, as seen in dysbio-
de Moreno de LeBlanc A et al . Effect of probiotics on intestinal microbiota
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sis, may increase the prevalence of  diseases not only of  
the mucosa but also within the body due to the strong 
interactions with the gut immune system, the largest im-
mune organ of  the body[9]. Such abnormalities have been 
pinpointed as etiological factors in a wide range of  dis-
eases, including autoimmune disorders, allergy, irritable 
bowel syndrome, inflammatory bowel disease, obesity, 
and colon cancer. The intestinal mucosa is the body’s first 
line of  defense against pathogenic and toxic invasions 
from food. After ingestion, orally administered antigens 
encounter the GALT (Gut Associated Lymphoid Tissue), 
which is a well-organized immune network that protects 
the host from pathogens and prevents ingested proteins 
from hyperstimulating the immune response through a 
mechanism called oral tolerance. The main mechanism 
of  protection given by the GALT is humoral immune 
response mediated by secretory IgA (s-IgA) which pre-
vents the entry of  potentially harmful antigens, while also 
interacting with mucosal pathogens without potentiating 
damage. The stimulation of  this immune response could 
thus be used to prevent certain infectious diseases that 
enter the host through the oral route. Numerous stud-
ies have shown that certain probiotic strains can increase 
s-IgA and modulate the production of  cytokines (media-
tors produced by immune cells) that are involved in the 
regulation, activation, growth, and differentiation of  im-
mune cells and have recently been reviewed[10].
Inflammatory bowel diseases (IBD), such as Crohn’s 
disease (CD), ulcerative colitis (UC) or irritable bowel 
syndrome (IBS) can arise from the disruption of  immune 
tolerance to the gut commensal microbiota, leading to 
chronic intestinal inflammation and mucosal damage in 
genetically predisposed hosts[11,12]. The gut microbiota 
composition and activity of  IBD patients are abnormal, 
with a decreased prevalence of  dominant members of  
the human commensal microbiota (i.e., Clostridium IXa 
and Ⅳ groups, Bacteroides, Bifidobacteria) and a concomi-
tant increase in detrimental bacteria (i.e., Sulphate-reducing 
bacteria, Escherichia coli)[13]. Enterobacteria and Bacteroides 
species have been implicated as important factors in the 
observed dysbiosis and in the development and recur-
rence of  IBD[14]. The observed dysbiosis is concomitant 
with defective innate immunity and bacterial killing (i.e., 
reduced mucosal defensins and IgA, malfunctioning 
phagocytosis) and overaggressive adaptive immune re-
sponse (due to ineffective regulatory T cells and antigen 
presenting cells), which are considered the basis of  IBD 
pathogenesis. 
Changes in the equilibrium of  the intestinal micro-
biota were also associated to the presence of  CRC. A 
comparative study of  the stool microbioma of  healthy 
individuals and CRC patients showed that butyrate-
producing bacterial species were under-represented in 
the CRC samples and this finding was correlated with 
proportionately lower amounts of  butyrate and higher 
concentrations of  acetate in stools of  CRC patients, 
compared to the healthy individuals[15]. These results 
agree with the conception that butyrate is a microbial me-
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Figure 1  Causes of gastrointestinal tract microbiota dysbiosis and effect on host health. GIT: Gastrointestinal tract; NAFLD: Non-alcoholic fatty liver disease; 
IBD: Inflammatory bowel diseases; IBS: Irritable bowel syndrome; CDV: Canine distemper virus.
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ome modifying early life events to subsequent obesity 
risk provide some indirect evidence to support a causal 
role for gut microbiota in the pathogenesis of  obesity[24]. 
Published data have proposed that dysbiosis of  gut mi-
crobiota (at phyla, genus, or species level) affects host 
metabolism and energy storage stating that among the 
mechanisms involved, metabolic endotoxemia (higher 
plasma LPS levels), gut permeability and the modulation 
of  gut peptides (GLP-1 and GLP-2) have been proposed 
as putative targets[25]. The mechanisms by which the gut 
microbiota affects metabolic disorders such as obesity, di-
abetes, and cardiovascular diseases have been proposed to 
be by two major routes: (1) the innate immune response 
to the structural components of  bacteria [e.g., lipopoly-
saccharide (LPS)] resulting in inflammation; and (2) bac-
terial metabolites of  dietary compounds (e.g., SCFA from 
fiber), which have biological activities that regulate host 
functions[26]. The concept of  crosstalk, the biochemical 
exchange between host and microbiota, is also important 
to understand obesity since it maintains the metabolic 
health of  the superorganism and whose dysregulation is a 
hallmark of  the obese state[27].
Since the GIT and liver are connected by the portal 
venous system, the liver is thus more vulnerable to trans-
location of  bacteria, bacterial products, endotoxin or 
secreted cytokines present in the GIT[8]. An obesogenic 
microbiota can alternate liver function by stimulating 
hepatic triglyceride and modulating systemic lipid me-
tabolism that indirectly impact the storage of  fatty acids 
in the liver[28]. A recent systematic database search was 
conducted and demonstrated that common mechanisms 
are involved in many of  the local and systemic manifesta-
tions of  NAFLD that can lead to an increased cardio-
vascular risk, and IBS, leading to microbial dysbiosis, im-
paired intestinal barrier and altered intestinal motility[29].
Studies in patients and animal disease models are 
shedding new light on the critical roles of  the microbiota, 
metabolome and host responses in primary and recur-
rent Clostridium difficile (C. difficile) infection (CDI), which 
is the leading cause of  antibiotic-associated diarrhea and 
pseudomembranous colitis in the healthcare setting[30]. In 
a recent study, culture-independent pyrosequencing was 
used to compare the distal gut microbiota for individuals 
with CDI, subjects with C. difficile-negative nosocomial 
diarrhea (CDN), and healthy control subjects[31]. This ge-
nomic analysis revealed significant alterations of  organ-
ism lineages in both the CDI and CDN groups, which 
were accompanied by marked decreases in microbial di-
versity and species richness driven primarily by a paucity 
of  phylotypes within the Firmicutes phylum. Normally 
abundant gut commensal organisms, including the Rumi-
nococcaceae and Lachnospiraceae families and butyrate-
producing C2 to C4 anaerobic fermenters, were signifi-
cantly depleted in the CDI and CDN groups.
These examples of  the effects of  microbiota dysbio-
sis are just a few of  the most recent studies published on 
the subject and show the immense lack of  knowledge of  
the effect of  the holobiont on human health. Correcting 
tabolite reported to have anti-tumorigenic effects, which 
were associated to the decrease of  colonic inflammation, 
the reinforcement of  the colonic barrier and the decreas-
ing of  oxidative stress[16]. Similar results were recently 
observed using a 1,2-dimethylhydrazine (DMH)-induced 
colon cancer model in rats. The animals from tumour 
group showed reduction of  butyrate-producing bacteria 
such as Roseburia and Eubacterium in the gut microbiota. 
This experimental work also showed that DMH-induced 
carcinogenesis was associated to decrease of  other ben-
eficial species such as Ruminococcus and Lactobacillus in the 
gut microbiota of  the rats[17]. New studies continue to 
show the differences in the intestinal microbiota between 
healthy individual and CRC patients. In this sense, it was 
described that a reduction of  biodiversity and richness of  
microbial community, with increases of  bacteroides was 
associated with colon cancer[18]. The analysis of  the exact 
mechanisms by which these changes in the intestinal mi-
crobiota can be related to colon carcinogenesis are largely 
unknown. It was demonstrated that in CRC patients, in 
addition to the modification of  intestinal metabolites, 
changes in the intestinal microbiota influence the host’s 
immune response. In this sense, it was demonstrated that 
IL-17C has an important role in microbiota-mediated 
tumorigenesis[19]. IL-17C was upregulated in human CRC 
samples and also in mouse models of  CRC. IL-17C was 
induced in the intestinal epithelial cells by the dysregu-
lated microbiota and promoted the survival of  these cells, 
contributing to the tumorogenesis. 
A detailed microbiota analysis of  a well-characterized 
cohort of  infants with food allergy (FA) showed that dys-
biosis of  fecal microbiota with several FA-associated key 
phylotypes, but not the overall microbiota diversity, may 
play a pathogenic role in FA[20]. In this study, the propor-
tion of  abundant Bacteroidetes, Proteobacteria, and Actinobac-
teria phyla were significantly reduced, while the Firmicutes 
phylum was highly enriched in the FA group. 
Recent studies have suggested that an imbalance of  
the intestinal microbiota may be involved in the develop-
ment of  obesity and type 2 diabetes mellitus (T2DM). In 
a recent review it was stated that a high-fat diet may in-
duce dysbiosis, which can result in a low-grade inflamma-
tory state, obesity and other metabolic disorders and that 
modifying this diet can play a role in T2DM management 
due to positive intestinal microbiota modulation[21]. Also, 
a metagenome-wide association study analysis showed 
that patients with type 2 diabetes were characterized by 
a moderate degree of  gut microbial dysbiosis, a decrease 
in the abundance of  some universal butyrate-producing 
bacteria and an increase in various opportunistic patho-
gens, as well as an enrichment of  other microbial func-
tions conferring sulphate reduction and oxidative stress 
resistance[22].
In another study, it was suggested that the obesity 
epidemic in the United States may be partly driven by the 
mass exposure of  Americans to foods containing low-
residue antimicrobial agents that can alter the composi-
tion of  the gut microbiota[23]. Studies that link microbi-
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this dysbiosis is now the aim of  many groups due to the 
diverse diseases that are directly or indirectly associated 
with this imbalance of  the symbiotic microbiota.
PROS AND CONS OF FECAL 
TRANSPLANTATION ON THE INTESTINAL 
MICROBIOTA AND DISEASE
Fecal transplantation and synthetic microbiome trans-
plants are being considered as promising therapies for 
dysbiosis-associated diseases.
Fecal microbial transplantation (FMT) is the process 
of  transplantation of  fecal bacteria from a healthy donor 
into a host with disease. Clinical criteria for inclusion and 
exclusion of  both donor and recipient should be per-
formed to limit the risk associated to this procedure and 
increase the chances of  success[32]. Fecal transplantation 
represents a therapy with a high potential of  success, and 
has been mostly studied in the treatment of  chronic gas-
trointestinal infections[33]. The effectiveness of  FMT was 
remarkable for recurrent C. difficile infection. Recently, it 
was reported that FMT was effective to improve clinical 
symptoms and eliminated fecal C. difficile toxins in a study 
of  27 patients with recurrent C. difficile infection who 
were given a single session of  FMT[34]. This effect was as-
sociated to increased microbial diversity in all the patients 
and the effectiveness was also associated to the correc-
tion of  the metabolism of  bile salts that is disrupted in 
patients with recurrent C. difficile infection[35].
Considering that microbial dysbosis is associated to 
many intestinal and non-intestinal diseases, FMT was 
considered for treatment of  different disorders, including 
IBS, IBD, insulin resistance, multiple sclerosis, obesity, 
and heart diseases[36]. However, its use remains controver-
sial in patients with IBD[37]. There is a study showing the 
safety and positive clinical response after FMT in children 
and young adults with UC[38]. A totally different response 
was also reported where the case of  a patient with UC 
(quiescent for more than 20 years) who was treated with 
FMT for a C. difficile infection and developed a flare of  
UC, indicating the need to be cautious in the use of  this 
procedure in patients with IBD[39]. It was also suggested 
the value of  characterizing not only the composition but 
also the temporal dynamics of  the microbiota for a bet-
ter understanding of  FMT efficacy in the treatment of  
UC[40].
The current knowledge shows that FMT has a high 
potential to be used[41], but controlled trials of  FMT in 
specific disorders and complemented by animal models 
of  fecal transplantation, in which variables can be con-
trolled and manipulated, are needed before FMT can 
be more accepted and applied clinically. Concerns over 
donor-derived infections (especially viral infection that 
are not normally detected) also exist, and it is difficult 
to quantify the true risk. The possibility to modify the 
transplantation of  whole microbial communities from a 
healthy donor stool by another methodology has also re-
cently been suggested in which specific fecal microorgan-
isms grown in vitro could afterwards be transplanted[42]. 
The discovery of  these commensal microorganisms will 
lead to the development of  new probiotics that can re-
place FMT as applied today.
EFFECT OF PROBIOTIC ADMINISTRATION 
ON THE INTESTINAL MICROBIOTA AND 
DISEASE
Probiotic microorganisms have been growing in popular-
ity due to increasing numbers of  studies proving that cer-
tain strains present health promoting properties, among 
them the beneficial balance of  the intestinal microbiota 
that can be also associated to other benefits to the host 
(Figure 2A). The most commonly used strains as probiot-
ics are members of  Lactobacilli, Enterococci and Bifidobacteria 
groups[43]. Lactic acid bacteria (LAB) represent a hetero-
geneous group of  microorganisms that are present in the 
normal diet of  many people and also in the gastrointes-
tinal and urogenital tract of  animals, and some of  these 
claimed to be probiotics. Although most of  the studies 
about probiotic have been mainly focused on bacteria, 
there are also many reports showing the potential of  pro-
biotic yeasts. In this context, Ianiro et al[44] reviewed the 
role of  the “gut mycome”, and demonstrated that intesti-
nal yeasts fulfill an important role in health maintenance. 
Selected yeast strains, especially from Saccharomyces boulardii 
were reported as probiotic, and their beneficial effects 
against different types of  diarrhea were demonstrated us-
ing experimental animal models[45] and also in human tri-
als[46,47]. Currently, many products containing LAB or oth-
er probiotic microorganisms are available on retail shelves 
throughout the world because of  the increase consumer 
demand for healthier natural foods that can improve their 
overall well-being.
EFFECTS OF PROBIOTICS ON 
INTESTINAL DISEASES
It has been shown that LAB and other probiotic mi-
croorganims can counteract inflammatory processes in 
the gut by stabilizing the microbial environment and the 
permeability of  the intestinal barrier, and by enhancing 
the degradation of  enteral antigens and altering their im-
munogenicity[48]. Lactobacillus reuteri (L. reuteri) was used 
to prevent colitis in IL-10 knock-out (KO) mice and to 
increase the number of  lactobacilli in the gastrointesti-
nal tract[49]. The normalization of  Lactobacillus levels was 
obtained by oral administration of  a prebiotic and rectal 
swabbing with L. reuteri to neonatal IL-10 KO mice. In a 
placebo-controlled trial, orally administered L. salivarius 
UCC118 reduced prevalence of  colon cancer and muco-
sal inflammatory activity in IL-10 KO mice by modifying 
the intestinal microbiota in these animals with reduction 
in C. perfringens, coliforms, and enterococcus levels in the 
probiotic fed group[50]. The administration of  yoghurt, 
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with potential probiotic strains, decreased the inflamma-
tion by modulation of  the host immune response in a 
trinitrobenzene sulphonic-induced mouse model of  IBD. 
This effect was related to beneficial changes in the large 
intestine microbiota of  the mice, with increases of  bifi-
dobacteria population[51].
The translation of  the potential use of  probiotics 
for IBD patients remains uncertain[52], and even when 
some authors reported their effectiveness against specific 
pathologies and the modification of  GIT microbiota is 
one of  the benefits attributed to them, there are only 
few reports where the fecal microbial composition of  
the patients was evaluated. A randomized, double-blind, 
placebo-controlled trial evaluated the effect of  a pro-
biotic mixture containing L. acidophilus, L. plantarum, L. 
rhamnosus, Bifidobacterium breve (B. breve), B. lactis, B. longum, 
and Streptococcus thermophilus in patients with IBS[53]. The 
fecal flora composition was analyzed by polymerase 
chain reaction denaturing gradient gel electrophoresis 
(DGGE) and it was reported that the therapeutic effect 
of  this probiotic mixture was associated with the stabi-
lization of  intestinal microbiota. Another study showed 
that probiotic supplementation (Ecologic 825, Winclove, 
Amsterdam, the Netherlands) to patients with UC and 
severe pouchitis restored the mucosal barrier, which was 
correlated with the bacterial diversity of  mucosal pouch 
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Figure 2  Effect of probiotic administration on gastrointestinal tract  dysbiosis (A) or healthy individuals (B) and the interaction of the gastrointestinal tract 
microbiota with the host. GIT: Gastrointestinal tract; FMT: Fecal microbial transplantation.
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microbiota[54]. 
Regarding the use of  probiotic yeasts, the influence 
of  the administration of  Saccharomyces boulardii on the 
composition of  the fecal microbiota was evaluated in a 
human microbiota-associated mouse model. The animals 
received antibiotic treatment that induced modifica-
tions in the intestinal microbiota. The administration 
of  probiotic yeast was related with quicker return to the 
initial level for the Clostridium coccoides-Eubacterium rectale 
and Bacteroides-Porphyromonas-Prevotella groups, 
compared to the control animals without any special ad-
ministration, and this effect was suggested as a possible 
mechanism by which S. boulardii affect beneficially human 
with antibiotic-associated diarrhea[55].
The use of  probiotic S. boulardii was also examined 
in humans, but as was explained for probiotic bacteria, 
not many studies in human analyzed the modification of  
the intestinal microbiota. Regarding IBD patients,  it was 
reported that S. boulardii was effective to reduce symp-
toms of  disease and this was related to the improvement 
of  intestinal microbiota composition[56]. S. boulardii was 
also evaluated for the treatment of  diarrhea-predominant 
IBS and its effect was compared to mesalazine[57].  It 
was reported that all the treatments improved the symp-
toms of  the patients; however, mesalazine alone or its 
combination with S. boulardii was more effective that the 
treatment with the probiotic yeast alone. A recent work 
demonstrated that probiotic S. boulardii, associated to 
conventional treatment improved the quality of  life of  
patients with diarrhea-dominant IBS[58]. This effect was 
associated to an anti-inflammatory profile of  cytokines 
in blood and tissues of  patients that receive the probiotic 
compared to the placebo group.
EFFECTS OF PROBIOTICS ON 
NON-INTESTINAL DISEASES
The use of  probiotics to beneficially affect the GIT 
microbiota was also evaluated in non-intestinal diseases 
(Figure 2B). Recent studies suggested that GIT microbio-
ta might play a critical role in the development of  obesity 
and LAB were pointed as candidate for an anti-obesity 
effect[59]. A review from 61 original articles showed that 
the main effect observed at the microbiota level (usually 
accompanied by weight loss) after probiotic or prebiotic 
administration in obese hosts was associated to increases 
in bifidobacteria populations[60].
Studies in diet induced obese mice showed that the 
supplementation of  L. curvatus HY7601 and L. planta-
rum KY1032 reduced the obesity and modulated pro-
inflammatory and fatty acid oxidation-related genes in the 
liver and adipose tissue; and this effect was associated to 
modulation of  gut microbiota[61]. The relative abundance 
of  4 species belonging to the Ruminococcaceae and 
Lachnospiraceae families of  the order Clostridiales and 
phylum Firmicutes were decreased by high fat diet and 
increased in mice receiving probiotic treatment. It was 
also observed that other GIT microbial species not asso-
ciated with changes caused by high fat diet were affected 
in mice that received probiotics, standing out the relative 
abundance of  endogenous Bifidobacterium pseudolongum.
VSL#3 is a mixture containing eight different strains 
of  probiotic bacteria that was evaluated against different 
diseases, including the prevention and treatment of  obe-
sity and diabetes in several mouse models. This effect was 
associated to the modulation of  the gut microbiota-short 
chain fatty acid (SCFA)-hormone axis[62]. VSL#3 supple-
mentation induced changes in the microbiota that were 
associated with an increase in the levels of  butyrate, and it 
was demonstrated in vitro that this SCFA stimulated the re-
lease of  GLP-1 from intestinal cells. The hormone GLP-1 
reduces food intake and improves glucose tolerance.
Recently, the beneficial effect of  L. coryniformis 
CECT5711 was demonstrated in a high fat diet induced 
mouse model. Probiotic administration to obese mice 
induced marked changes in microbiota composition and 
reduced the metabolic endotoxemia by decrease of  the 
LPS plasma level[63]. 
The effect of  probiotics in humans was also ob-
served; however, as was explained for other pathologies, 
there are not many articles that evaluate the intestinal 
microbiota. A clinical trial with the probiotic bacterium 
L. salivarius Ls-33 was conducted in obese adolescents 
to investigate the impact on fecal microbiota[64]. Ratios 
of  Bacteroides-Prevotella-Porphyromonas group to Fir-
micutes belonging bacteria were significantly increased 
after administration of  Ls-33; however, these changes 
were not related to effects on their metabolic syndrome.
A randomized, double-blind, placebo controlled study 
was conducted in order to evaluate the effects of  pro-
biotic capsule when combined with herbal medicine in 
treatment of  obesity[65]. In this trial, each probiotic capsule 
contained viable cells Streptococcus thermophillus, L. plantarum, 
L. acidophilus, L. rhamnosus, B. lactis, B. longum, and B. breve. 
It was reported that probiotic administration prevented 
endotoxin production, which can lead to GIT microbiota 
dysbiosis associated with obesity. Gut B. breve population 
showed negative correlation with endotoxin level.
NAFLD is a disease linked to obesity and the ben-
eficial role of  probiotics was also reported[66]. Recently, 
it was shown that L. rhamnosus GG protected against 
NAFLD in a mice model[67]. The effect was associated 
to increase total bacterial numbers including the phyla 
Firmicutes and Bacteroidetes in the distal small intestine. 
This result was in concordance to the previous one that 
reported modulation of  the microbiota in the small in-
testine with a concomitant anti-obesity effect in mice that 
received L. rhamnosus GG and L. sakei NR28[68].
The human GIT microbiota has also been related 
with a possible cardiovascular risk. GIT microbiota pro-
files were not only associated with metabolic diseases, but 
also the flux of  metabolites derived from microbial me-
tabolism of  choline, phosphatidylcholine and l-carnitine 
that contribute directly to cardiovascular disease. In this 
sense, probiotics were reported among dietary strategies 
to modulate the GIT microbiota or their metabolic ac-
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tivities[69-71]. The improvement of  disease biomarkers, es-
pecially plasma cholesterol levels, appears to be possible 
after probiotic administration to lower cardiovascular 
risk. In this sense, it was shown that the administration 
of  a probiotic soy product containing Enterococcus faecium 
CRL 183 and L. helveticus 416 supplemented or not with 
isoflavones was associated with an improved cholesterol 
profile and inhibition of  atherosclerotic lesion develop-
ment in a rabbit model[72]. The authors reported that of  
Enterococcus spp., Lactobacillus spp. and Bifidobacterium spp. 
were negatively correlated with total cholesterol, non-
HDL-cholesterol, and lesion size. The intake of  the pro-
biotic soy product increased significantly these bacterial 
species in the fecal microbiota.
EFFECTS OF PROBIOTICS IN HEALTHY 
HOSTS
There are also reports that showed the potential of  pro-
biotics in healthy hosts, maintaining a balanced microbio-
ta, which, as was explained above, is an important key for 
health. The consumption of  a probiotic product contain-
ing L. coryniformis CECT5711 and L. gasseri CECT5714 
was analyzed in 30 children with no gastrointestinal pa-
thology[73]. An increase in faecal lactobacilli counts was 
shown at the end of  the experimental protocol, and these 
findings were associated to enhancing the defence against 
gastrointestinal aggressions and infections and enhancing 
the immune function with increase IgA concentration in 
faeces and saliva. A recent work reported a clinical trial 
that included 40 participants with no known digestive 
diseases. Laminaria japonica, a widely used ingredient in 
seaweed kimchi, and LAB of  traditional fermented Ko-
rean food were given to volunteers and was related to in-
creases in the number of  some administered LAB species 
in their GIT microbiota[74].
CONCLUSION
The dysbiosis of  the gastrointestinal tract microbiota 
is considered to be one of  the contributing factors in 
the development of  certain gastrointestinal and non-
gastrointestinal diseases. Fecal transplantations appear to 
be promising therapies for dysbiosis-associated diseases; 
however, controlled trials of  FMT in specific disorders 
are needed before FMT can be more accepted and ap-
plied clinically. The possibility to modify the traditional 
FMT by specific probioitc fecal microorganisms was also 
reported and would be a better alternative from a safety 
and therapeutic point of  views.
Recent reports showed the potential of  the adminis-
tration of  specific probiotic strains to improve the bal-
ance of  the GIT microbiota that is altered in different 
diseases, being IBD and obesity the pathologies in which 
there are more studies showing this association using 
animal models and even in human clinical trials. The im-
portance of  probiotic consumption in healthy hosts was 
also demonstrated because its relationship with beneficial 
balance in GIT microbial populations, which is also as-
sociated to improved defense against gastrointestinal ag-
gressions and infections and the enhancing of  the host’s 
immune function.
However, as was explained for FMT, there are not 
enough human trials where the application of  probiotics 
as biotherapeutic agents was evaluated in double-blinded 
large scale clinical trials. These assays are very important 
before the medical community will accept the addition 
of  probiotic as supplements for specific patients with 
diseases associated to gut microbial dysbiosis as a viable 
alternative to FMT.
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